Edge
StocktwitsEarnings

Official STOCKTWITS Representative
$MNKD Q1 '25 Earnings Results & Recap
MannKind Corp. reported Q1 2025 EPS of $0.04, met estimates for $0.04, and revenue of $78 million, came in above the $76.02 million estimate; key outlooks include strong growth in the endocrine business, ongoing commercialization of Afrezza, and significant revenue potential from the pediatric Afrezza indication and the Tyvaso DPI collaboration.1
3
